| Schedule 1:1 meetings with target speakers before events | Action Item | — | — | networking, preparation, project-management, strategy, drug-development, earned-value, life-sciences, ppm | 14 Mar 2026 |
Edit
|
| FDA MDR convergence creating compliance gaps | Key Insight | — | — | regulatory, FDA, MDR, compliance, safety, post-market-surveillance, safe, life-sciences, medtech, regulatory-affairs, safety-professionals, ppm | 14 Mar 2026 |
Edit
|
| AI is reshaping portfolio decision-making velocity | Key Insight | — | — | AI, PPM, decision-velocity, ai, portfolio-management, project-management, clinical-trials, cro-cdmo, ppm, life-sciences, medtech, project-managers | 14 Mar 2026 |
Edit
|
| Audit your portfolio scoring model for strategic alignment gaps | Action Item | — | Katherine Olig | governance, strategy, portfolio, compliance, portfolio-management, project-management, programme-management, leadership, drug-development, ppm, okr, life-sciences, medtech, c-suite, project-managers, regulatory-affairs | 13 Mar 2026 |
Edit
|
| "Strategy without governance is a wish. Governance without strategy is bureaucracy." | Quote | — | Katherine Olig | governance, strategy, leadership, portfolio-management, project-management, programme-management, ppm, earned-value, life-sciences, medtech, project-managers, regulatory-affairs | 13 Mar 2026 |
Edit
|
| Session Recap: Embedding Strategy into Portfolio Governance | Summary | — | Katherine Olig | governance, strategy, portfolio, leadership, portfolio-management, project-management, programme-management, change-management, ppm, earned-value, life-sciences, medtech, project-managers, pmo, regulatory-affairs, keynote | 13 Mar 2026 |
Edit
|
| Identify 3 low-risk portfolio decisions to pilot AI-assisted analysis | Action Item | — | Aimee Rodrigues | ai, portfolio, digital-transformation, strategy, governance, risk-management, portfolio-management, project-management, leadership, resource-optimization, clinical-trials, drug-development, cro-cdmo, ppm, kpi, decision-velocity, life-sciences, pharma, medtech, c-suite, project-managers, regulatory-affairs | 12 Mar 2026 |
Edit
|
| AI is compressing portfolio review cycles from quarterly to continuous | Key Insight | — | — | ai, governance, portfolio, digital-transformation, portfolio-management, project-management, clinical-trials, drug-development, cro-cdmo, ppm, safe, earned-value, life-sciences, medtech, project-managers, pmo, regulatory-affairs | 12 Mar 2026 |
Edit
|
| Decision Velocity Index (DVI) — Assessment Framework | Resource | — | Aimee Rodrigues | ai, portfolio, strategy, digital-transformation, risk-management, portfolio-management, project-management, leadership, change-management, capacity-planning, resource-optimization, clinical-trials, drug-development, cro-cdmo, ppm, ooda, kpi, decision-velocity, life-sciences, medtech, c-suite, project-managers, regulatory-affairs, workshop | 12 Mar 2026 |
Edit
|
| Run a 2-week cross-functional capacity pilot across one product line | Action Item | — | — | capacity, portfolio, agile, portfolio-management, project-management, capacity-planning, resource-optimization, quality, clinical-trials, cro-cdmo, ppm, life-sciences, medtech, project-managers, breakout | 11 Mar 2026 |
Edit
|
| Session Recap: Accelerating Decision Velocity with Lean, Agile, and AI | Summary | — | Aimee Rodrigues | ai, agile, portfolio, decision-velocity, risk-management, portfolio-management, project-management, leadership, lean, clinical-trials, drug-development, cro-cdmo, ppm, ooda, kpi, lean-portfolio, safe, earned-value, life-sciences, medtech, project-managers, regulatory-affairs, r-and-d | 11 Mar 2026 |
Edit
|
| Cross-functional resource visibility is the #1 portfolio optimization lever | Key Insight | — | Matthew Palicki | capacity, portfolio, strategy, leadership, ai, portfolio-management, project-management, capacity-planning, resource-optimization, value-stream, quality, clinical-trials, cro-cdmo, ppm, earned-value, life-sciences, medtech, project-managers, regulatory-affairs, workshop | 10 Mar 2026 |
Edit
|
| "Resilient portfolios are not built during crises — they are stress-tested before them." | Quote | — | Besaint Sahni | risk, portfolio, leadership, strategy, ai, portfolio-management, project-management, ppm, life-sciences, medtech, project-managers, pmo | 9 Mar 2026 |
Edit
|
| Risk-Capacity Heat Map Template — Portfolio-Level Risk Visualization | Resource | — | Gianluca Puliti | risk, capacity, portfolio, governance, ai, risk-management, compliance, regulatory, portfolio-management, project-management, leadership, capacity-planning, resource-optimization, quality, clinical-trials, drug-development, cro-cdmo, ppm, safe, earned-value, life-sciences, pharma, medtech, c-suite, project-managers, regulatory-affairs, r-and-d | 9 Mar 2026 |
Edit
|
| Session Recap: Enterprise Risk, Capacity, and Synergy Management | Summary | — | Gianluca Puliti | risk, capacity, portfolio, governance, ai, risk-management, compliance, regulatory, portfolio-management, project-management, strategy, leadership, capacity-planning, resource-optimization, quality, clinical-trials, drug-development, cro-cdmo, ppm, earned-value, life-sciences, medtech, c-suite, project-managers, regulatory-affairs, r-and-d, panel | 9 Mar 2026 |
Edit
|
| Change management failure is the top reason PPM tool rollouts stall | Key Insight | — | Karen Forsha | leadership, digital-transformation, strategy, ai, portfolio-management, project-management, change-management, clinical-trials, drug-development, cro-cdmo, cost-management, ppm, earned-value, life-sciences, medtech, c-suite, project-managers, regulatory-affairs, r-and-d | 8 Mar 2026 |
Edit
|
| Value Stream Mapping Guide for Drug Development Programs | Resource | — | Lisamarie Manso | value-stream, digital-transformation, agile, strategy, governance, compliance, regulatory, portfolio-management, project-management, leadership, change-management, lean, drug-development, cmc, ppm, earned-value, pharma, manufacturing, c-suite, project-managers, regulatory-affairs, r-and-d, life-sciences | 7 Mar 2026 |
Edit
|
| Session Recap: Value Stream Management in Life Sciences | Summary | — | Lisamarie Manso | value-stream, portfolio, digital-transformation, agile, compliance, regulatory, portfolio-management, project-management, strategy, leadership, lean, drug-development, cost-management, ppm, kpi, earned-value, life-sciences, pharma, c-suite, project-managers, regulatory-affairs, r-and-d, keynote | 7 Mar 2026 |
Edit
|
| FDA-MDR regulatory divergence is the hidden portfolio risk multiplier | Key Insight | — | Mike Xie | compliance, risk, governance, strategy, ai, risk-management, regulatory, portfolio-management, leadership, resource-optimization, quality, safety, drug-development, safe, earned-value, life-sciences, medtech, c-suite, portfolio-leaders, regulatory-affairs, safety-professionals, ppm | 6 Mar 2026 |
Edit
|
| "High-performance teams do not happen by accident — they are architected." | Quote | High-Performance Project Teams: Culture, Collaboration, and Technology | Jen Hirsch | leadership, agile, strategy, portfolio-management, project-management, safety, ppm, safe, c-suite, project-managers, regulatory-affairs, safety-professionals, workshop, life-sciences | 5 Mar 2026 |
Edit
|